The
Emergency Contraception Newsletter
Spring
2002
Vol.
7, No. 1
This newsletter is prepared and distributed as a voluntary activity on
behalf of the American Society for Emergency Contraception and the
international Consortium for Emergency Contraception. It is distributed
electronically twice each year to anyone wishing to receive it. To contribute a
news item, please send it to AmSocEC@aol.com, to Tara
Shochet (shochet@princeton.edu), or to Charlotte Ellertson (cellertson@popcouncil.org.mx).
We reserve the right to check and edit items as appropriate. To add or remove
your name from the newsletter circulation list, please write to
AmSocEC@aol.com. More information about ASEC and the Consortium is located at
the end of this newsletter.
Over the past three months, Plan B's distributors added several thousand
more pharmacies to the Plan B web-based pharmacy directory (www.go2planb.com).
The big increase was the result of a major promotion campaign designed to
improve availability at retail pharmacies across the country. A majority of
Contact:
Sharon L. Camp, PhD
Women's Capital Corporation
1990 M Street, NW,
USA
Tel: 202-969-8438
Fax: 202-969-8439
Email: scamp@go2planb.com
The expiration dating for PREVEN® Emergency Contraceptive Pills has been
extended to 48 months. The longer shelf life helps to facilitate women of
reproductive age keeping PREVEN® on hand, so that it is available if an
emergency contraceptive need arises. When EC's are taken shortly after unprotected sex,
maximum efficacy is achieved.
Contact:
Dawn M. Carone
Product Manager
Gynétics, Inc.
3371 Route One, Suite 200
Lawrenceville, NJ 08648
USA
Tel: 609-919-1931 ext. 100
Fax: 609-919-9409
Email: dcarone@gynetics.com
NorLevo, the dedicated levonorgestrel
emergency contraceptive product marketed by HRA Pharma,
is now available directly from a pharmacist in Finland, and will soon be in
Switzerland, without the need for a clinician's prescription. Continuing its
expansion around the globe, NorLevo has recently been
approved as a prescription drug in
Contact:
André Ulmann
HRA Pharma
19, rue Frédérick Lemaitre
75020
Tel: 33-1-40-33-1130
Fax: 33-1-40-33-1231
Email: infohra@hra-pharma.com
In the
Contact:
Anne Webb
Abacus Centre for Contraception and Reproductive Health
Email: awebb@westkirby1.freeserve.co.uk
In April 2002, Contech Devices Pvt. Ltd., in
collaboration with HRA Pharma, officially launched NorLevo emergency contraceptive pills in
Contact:
S. M. Buch
Contech Devices Pvt. Ltd.
A-46/47, Sector-57
Noida-201 301
INDIA
Tel: 91-120-4581136,
4581336, 4581287
Fax: 91-120 4581296
Email: ception@del2.vsnl.net.in
Starting in late July 2002, women in
Contact:
Alyson Browett
Kaiser Daily Reproductive Health Report
Tel: 202-672-5952
Fax: 202-672-5767
Email: dailyreports@kaisernetwork.org
As of May 2002,
Contact:
Sharon Cohen
Pharmacy Access Partnership
USA
Tel: 510-272-0150, Ext. 103
Fax: 510-272-0285
Email: scohen@phi.org
Under the pressure of the Catholic Church, the
Contact:
André Ulmann
HRA Pharma
19, rue Frédérick Lemaitre
75020
Tel: 33-1-40-33-1130
Fax: 33-1-40-33-1231
In March 2002, the Supreme Court of Argentina ruled against the production
and commercialization of Imediat, a combined EC
product, which had been sold since September 1997. Such procedure was motivated
by their assumption that this product is abortifacient.
This prohibition applies only to Imediat and not to Imediat N, a
levonorgestrel-only EC product, which was introduced into the Argentine
market in September 2000. Given this situation, it was the company's decision
to replace Imediat with Imediat
N, in view of its advantages regarding efficacy and tolerability over the
combined product. Therefore, Imediat N is commercialized
all over the country and hence, it is available to every Argentine woman.
Contact:
Valentina Carricarte
Product Manager - Hormonal Line
Gador S.A.
Darwin 429
1414 Buenos Aires
ARGENTINA
Tel: 54-11-4858-9000
Email: vcarricarte@gador.com.ar
On
Contact:
Dr. Colleen Murphy
Project Leader
Tel: 907-243-1939
Email: drcolleen@gci.net
Web: http://www.akemergencycontraception.org
The Pharmacy Access Partnership's EC Program in
Contact:
Jane Boggess, PhD
Director
Pharmacy Access Project
Tel: 510-272-0150
Email: jboggess@phi.org
Together with over 130 national, state and local organizations, the
Reproductive Health Technologies Project (RHTP) launched “Back Up Your Birth Control” Day on
Contact:
Stacy Robison
Reproductive Health Technologies Project
USA
Tel: 202-557-3416
Fax: 202- 728.4177
Email: stacy@rhtp.org
The Association of Reproductive Health Professionals
(ARHP), the official managing organization for the Emergency Contraception
Hotline (1-888-NOT-2-LATE) and Website (http://not-2-late.com) continues to
work on increasing the provider database, promoting the EC Hotline and Website,
and increase funding. ARHP was part of a coalition of organizations that
launched the ongoing Back up your Birth Control campaign, which features the
Hotline and Website. ARHP is currently working with the
Contact:
Natalia Barolin
Communications Coordinator
Association of Reproductive Health Professionals
USA
Tel: 202-466-3825
Fax:
202-466-3826
Email: nbarolin@arhp.org
Web: http://www.arhp.org
For the 2001-2002 academic year, Planned Parenthood
Federation of America received a grant to raise awareness among college
students about emergency contraception. Twenty-six PPFA affiliates
participated in the campaign, educating students at over 40 schools about EC
through ad placement, tabling on campus, residence hall presentations, peer
educator trainings, and other events. In addition, 19 affiliates participated
in the Back Up Your Birth Control Campaign on March
20, providing further EC education on 31 campuses. PPFA has applied for another
grant to continue EC education on campus during the 2002-2003 academic year. A list of the targeted schools is available upon
request.
Contact:
Deborah Weiss
Campus Outreach Associate
Planned Parenthood Federation of
810
Tel: 212-261-4697
Fax: 212-247-6342
Web: http://www.plannedparenthood.org/vox/
The Open Society Institute's Program on Reproductive Health and Rights gave
almost
$1.3 million in EC-related grants in 2001 and the first quarter of 2002:
Advocates for Youth, $330,000 to raise awareness about emergency contraception
among young women nationally and in several key states (2001-2003); American
Civil Liberties Union Foundation of Pennsylvania, $14,775 to support
"Emergency Contraception for Rape Survivors: Policies to Ensure a Uniform
Standard of Care" (2001); Association of Reproductive Health
Professionals, $100,000 to support provider education initiatives on emergency
contraception and early abortion options (2001-2003); Center for Reproductive
Health Research and Policy, University of California, San Francisco, $183,166
to support clinical trials comparing the effects of three emergency
contraception service delivery methods on access, unintended pregnancy rates,
sexually transmitted disease rates, regular contraceptive usage, and frequency
of unprotected intercourse (2002-2003); NARAL/NY, $155,000 to support the
Campaign for Access for Emergency Contraception (2002-2003); Pacific Institute
for Women's Health, $50,000 to support "Increasing Demand for and Access
to Emergency Contraception and Medical Abortion in California"
(2002-2003); Planned Parenthood of Central and Northern Arizona, $114,000 to
support the Emergency Contraception and Medical Abortion Public Awareness
Campaign (2002-2003); ProChoice Resource Center, $150,000
to support EC Does It, a project to assist pharmacists and other grassroots
groups in promoting awareness of, and access to, emergency contraception
(2001-2003); Public Health Institute, $150,000 to support the Pharmacy Access
Partnership (2002-2003); Reproductive Health Technologies Project, $50,000 to
support "Demand Your EC" Day: An Activist Campaign (2001-2002).
Contact:
Tiana Norgren, Ph.D.
Program Officer
Program on Reproductive Health and Rights
Open Society Institute
400
Tel: 212-547-6994
Fax: 212-548-4677
Email: cnorgren@sorosny.org
The MergerWatch Project of the Education Fund of
Family Planning Advocates of NYS is working closely with the Clara Bell Duvall
Project of the ACLU of Pennsylvania to ensure the consistent offering of
emergency contraception to rape survivors receiving treatment at hospital
emergency departments. MergerWatch staff are
monitoring the progress of proposed legislation in various states and comparing
the outcome with alternative policy approaches, including regulation, voluntary
adoption of hospital policies and potential litigation strategies. The Duvall
Project is working to improve the relationship between pro-choice groups and
sexual assault survivor organizations in order to forge a coalition in support
of EC in the emergency departments' policies.
Contact:
Lois Uttley
Family Planning Advocates of NY State, MergerWatch
Project
Tel: 518-436-8408
Email: lois@mergerwatch.org
Advocates for Youth is currently working at
national, state, and local levels to raise awareness and improve access to
emergency contraception for adolescents. Advocates' national communications and
media strategy includes public service announcements, radio tours, and
briefings with producers and writers of teen-focused television shows to
encourage placement of story lines related to teens and EC. Advocates'
Clearinghouse on Adolescents and Emergency Contraception provides strategic
technical assistance, training, resources and networking opportunities to state
teen pregnancy prevention coalitions, sexuality educators, youth serving
professionals, and adolescent health providers. The Clearinghouse has developed
a number of publications related to EC use among adolescents, including: a Fact
Sheet for program planners with basic information on efficacy, mechanism of
action, public opinion, and barriers to teen access; an Issues at a Glance,
describing innovative efforts to increase teen access to EC and listing resources
for advocates and program planners; a teen pamphlet written by and for young
people answering frequently-asked questions about EC; and an issue of
Advocates' quarterly publication, Transitions, exploring pharmacists' attitudes
and awareness of EC for adolescents and offering a lesson plan for sexuality
educators.
Contact:
Tamarah Moss
Program Manager
Emergency Contraception Initiative
Advocates for Youth
Washington, DC 20005
USA
Tel: 202-347-5700
Fax: 202-347-2263
Email: tamarah@advocatesforyouth.org
Web: www.advocatesforyouth.org
The Emergency Contraception Access Campaign, a coalition of public health
advocates, lawmakers, medical and health professionals and community
organizations across
Contact:
Destiny Lopez
Emergency Contraception Access Campaign
NARAL/NY
462 Broadway,
Tel: 212-343-0114
Fax: 212-343-0119
Email: eccampaign@webcom.com
The Institute for Reproductive Health Access, a project of the NARAL/NY Foundation,
is running an EC Expansion Campaign with other state NARAL affiliates to create
new EC providers in unserved counties in New York,
Texas and Michigan. Working from research compiled by the state affiliates, the
project is contacting physicians practicing in counties with no identifiable EC
provider in order to gauge their interest in providing EC to their patients or
any woman in their area who may need it. Affiliates will work to cultivate
interested physicians and provide them with the necessary information in order
to help them integrate EC in their practice and to list themselves with
referral services such as 1-888-NOT-2-LATE.
Contact:
Mary Alice Carter
NARAL/NY
462 Broadway,
Tel: 212-343-0114
Fax: 212-343-0119
Email: macarter@naralny.org
In February 2001, Family Health International (FHI) and the North Carolina
Planned Parenthood affiliates launched a Dial EC project in order to 1)
increase awareness of and access to emergency contraceptive pills for women in
Contact:
Elizabeth Raymond, MD
Family Health International
USA
Tel: 919-544-7040
Fax: 919-544-7261
Email: eraymond@fhi.org
This summer, the International Consortium for Emergency Contraception is
working to compile more complete information on EC activities currently
underway or recently completed by member organizations and those of other large
multinational organizations working in
Contact:
Susan McIntyre, Coordinator
International Consortium for Emergency
Contraception
C/o Family Health International
Email: smcintyre@fhi.org
In April 2002, the Inter-American Parliamentary Group on Population and
Development (IAPG) in collaboration with the Asociación
Chilena de Protección de la
Familia (APROFA) and with financial support provided
by UNFPA and IPPF/WHR, organized a meeting of
parliamentarians on EC in
Contact:
Giselle Carino
Program Associate
IPPF/WHR
Tel: 212-214-0220
Fax: 212-248-4221
Email: gcarino@ippfwhr.org
Web: www.ippfwhr.org
The Pacific Institute for Women's Health continues to work with women's
groups, youth organizations and service providers in Latin America including
Mexico, Nicaragua, El Salvador, Guatemala and Brazil to advocate for emergency
contraception (EC) as a women's sexual and reproductive right and to
disseminate information about EC in the context of women's sexuality and the
prevention of STI/HIV and violence. In addition, the Institute is facilitating
training for the media in
Contact:
Angeles Cabria
Senior Program Officer for
Responsable de Programas para
America Latina
Pacific Institute for Women's Health
Coordinator / Coordinadora
Latin American Consortium for Emergency Contraception
Consorcio Latinoamericano de
Anticoncepción de Emergencia
3450 Wilshire Boulevard, suite
1000
Los Angeles, CA 90010-2208
USA
Tel: 213-386-2600, Ext. 4807
Fax: 213-386-2664
Email: acabria@piwh.org
Web: http://www.piwh.org
A new publication from IPPF/WHR describes Profamilia/Colombia's
experience of promoting emergency contraception from a sexual and reproductive
rights perspective. Their strategies included training providers, registering
and marketing Postinor 2 (a levonorgestrel
dedicated product), building coalitions with women's groups, and medical and
scientific associations and informing the media. Profamilia
also fought opposition from the church with sound legal and scientific
arguments. The publication showcases letters and petitions by both groups for
and against EC. Lastly, the publication offers recommendations for other
organizations seeking to promote EC in the legal, medical, scientific,
communications and social marketing arenas. Available at no
cost; in Spanish only.
Contact:
Giselle Carino
Program Associate
IPPF/WHR
Tel: 212-214-0220
Fax: 212-248-4221
Email: gcarino@ippfwhr.org
Web: www.ippfwhr.org
The United Nations Health and Community Section is
in the process of finalizing a guide entitled "Clinical Management of
Survivors of Rape: A guide to the development of protocols for use in refugee
and internally displaced person situations." This document is produced in
conjunction with WHO and the Inter-agency Working
Group on Reproductive Health in Refugee Situations. Its purpose is to assist
field actors in developing a protocol for the clinical management of survivors
of rape based on international standards and host country laws and procedures.
To obtain this document, please address your request to:
UNHCR - Health and Community Development Section
C.P. 2500
1202
Fax: 41 22 739 7366
Email: HQTS00@unhcr.ch
or
World Health Organization
Department of Reproductive Health and Research
Avenue Appia
1211
Fax: 41 22 791 4189
Email: rhrpublications@who.int
The Population Council's Frontiers Program is organizing and funding a
training workshop on EC, during the Latin American Consortium for Emergency
Contraception (LACEC) Conference, to take place in
Contact:
Toni Martin
Regional Communications Officer
Fronteras of Reproductive Health
Population Council
Escondida 110
Villa Coyoacán
México DF, 04000
MEXICO
Tel: 5255-5554-8610
Email: tmartin@popcouncil.org.mx
Over the past two years, PSI piloted a comprehensive, community-based
approach to promoting emergency contraception in Portland, OR and Sacramento,
CA. PSI combined strategic community mobilization, a media campaign and health
worker training (clinical and non-clinical providers) to increase awareness of
EC as a means of reducing unintended pregnancies and abortions. The final
evaluation of this promotion project showed an increase in EC awareness and
access on several different levels. For instance, during the media campaign,
calls to the 1-888-NOT-2-LATE EC Hotline tripled in the
Contact:
John Beleutz
Director of US Programs
Population Services International
Tel: 831-722-1878
Fax: 831-722-9279
Email: jbeleutz@psicc.org
FHI is collaborating with investigators from
Contact:
Elizabeth Raymond, MD
Family Health International
USA
Tel: 919-544-7040
Fax: 919-544-7261
Email: eraymond@fhi.org
Providing EC in advance has been advocated to increase timely access and
improve efficacy, but there is concern over what impact dispensing advance EC
might have on adolescent sexual and contraceptive behaviors. This randomized
prospective study, conducted by researchers at the University of Pittsburgh School of Medicine, compares the sexual and
contraceptive behaviors of adolescent females who are given EC education and an
advance provision of EC vs. the Controls who receive EC education only. Each
subject received six monthly 10-minute telephone interviews to assess sexual
and contraceptive behaviors including unprotected intercourse, EC use, and
condom and OCP use over the past month. Contrary to some providers' concerns,
the Advance EC group did not report more frequent unprotected intercourse at
the 1 or the 6-month follow up. At the 1st month follow-up interview, there
were no significant differences in the frequency of unprotected intercourse or
condom or OCP use between the Advance EC group and the Control group. At the
6th month and final interview, the Advance EC group and Controls reported an
equal frequency of unprotected intercourse. However, the Control group (47%)
reported using OCP significantly more often than the Advance EC group
(33%). Conversely, the Advance EC group (77%) reported using condoms
significantly more than the Control group (62%). Across the entire study, the
Advance EC group reported using EC more often if it was needed, they began the
EC course more quickly than the Controls and reported fewer new pregnancies and
STDs. Providing advance EC does not appear to have any
detrimental impact on adolescent sexual or condom use behaviors. Study results
will be presented at North American Society of Pediatric and Adolescent
Gynecology national meeting, June 2002.
Contact:
Melanie A. Gold, D.O., FAAP, FACOP
Associate Professor of Pediatrics
Director of Family Planning Services
Director of Adolescent Medicine Research
Children's
Tel: 412-692-8504
Fax: 412-692-8584
Email: magold@pitt.edu
According to a new study in the British Medical Journal, educating teenagers
about emergency contraception does not lead to increased use of EC, nor does it
lead to an increase in levels of sexual activity. It does, however, increase
their knowledge about proper administration of the drugs. Researchers from the
University of Bristol, Cardiff University, and the University of Southampton
surveyed approximately 4,000 students in the United Kingdom ages 14 and 15. The
students were divided into two groups: one group received a lesson on EC while
the other group did not. Teachers with training in EC education gave students
in the experimental group a single lesson on the use of ECPs
and IUDs for emergency contraceptive purposes. Questionnaires on EC use and on
sexual activity were administered to both groups six months after the lesson. The proportion
of students who knew the correct time interval for both types of EC was
significantly higher in the experimental group than in the control group.
Furthermore, learning about EC did not lead to an increase in the students'
sexual activity or in the number of students who had either used EC or planned
to use it in the future. [Adapted from the
Contact:
Alyson Browett
Kaiser Daily Reproductive Health Report
Tel: 202-672-5952
Fax: 202-672-5767
Email: dailyreports@kaisernetwork.org
Last year, FHI conducted a study to assess comprehension of a prototype
over-the-counter package of Plan B ECPs. The study
showed that by reading the prototype label, most women could understand key
information necessary for safe and effective use of this product. A full report
of this study has now been accepted for publication in Obstetrics and
Gynecology. It is expected to come out in August.
Contact:
Elizabeth Raymond, MD
Family Health International
Tel: 919-544-7040
Fax: 919-544-7261
Email: eraymond@fhi.org
FHI has recently finished another study to estimate the frequency of
inappropriate use of Plan B when the product is dispensed under OTC-like
conditions. This study included more than 650 women at 5 Planned Parenthood
affiliates across the
Contact:
Elizabeth Raymond, MD
Family Health International
USA
Tel: 919-544-7040
Fax: 919-544-7261
Email: eraymond@fhi.org
Since September 19, 2000, Planned Parenthood of Maryland's Emergency
Contraception Hotline, 1-877-99-GO-4-EC, has provided over 9000 women with
information about EC and over 3100 women access to EC pills. Even though more
individuals are learning about EC in
Contact:
Emily P. Thompson
EC Project Coordinator
Planned Parenthood of
Tel: 410-576-2145
Fax: 410-576-7600
Email: emily.thompson@ppfa.org
The Clara Bell Duvall Reproductive Freedom Project is conducting research on
the availability of EC in
Contact:
Wendy Bennett / Carol Petraitis
The Clara Bell Duvall Project, ACLU-PA
Tel: 215-629-0111
Fax: 215-592-1343
Email: duvall@aclupa.org
In March 2000, the Association for the Prevention of Unwanted Pregnancies
("APPRENDE") launched Postinor-2 in
Contact:
Alan Spruyt
Family Health International
USA
Tel: 919-544-6979 x478
Fax: 919-544-7261
Email: aspruyt@fhi.org
A pharmacokinetic study of different dosing regimens of levonorgestrel
for emergency contraception was conducted at the PROFAMILIA clinic in
Contact:
Vivian Brache
Departamento de Investigación
Biomédica
Asociación Dominicana Pro
Bienestar de la Familia, Inc.
Socorro Sanchez 160, Zona 1
Santo Domingo
DOMINICAN REPUBLIC
Email: biomedica@codetel.net.do
Research on levonorgestrel undertaken by the
UNDP/UNFPA/WHO/ World Bank Special Programme of
Research, Development, and Research Training in Human Reproduction (HRP) is
continuing in three multicentre studies. A large
randomized, double-blind multinational study was completed during 2001, which
investigates, among other things, the efficacy and side effects of a single
dose of 1.5 mg (two tablets of 0.75 mg of levonorgestrel
taken as one dose) compared to the regimen when the tablets are taken at
12-hour interval. The third arm in this study is 10 mg mifepristone.
The treatment was given up to 120 hours of intercourse. A total of 4136 women
were enrolled in this study in 15 family planning clinics in
Contact:
Helena von Hertzen
World Health Organization
1211
Email: vonhertzenh@who.ch
The 12-hour interval between the two tablets is sometimes impractical and a
double-blind, multicentre study is, therefore,
investigating in China, whether this interval could be increased to 24 hours,
as this would be more convenient for women. The recruitment of over 2000 women
for this trial is expected to be completed by mid 2002.
Contact:
Helena von Hertzen
World Health Organization
1211
Email: vonhertzenh@who.ch
Researchers at the
Contact:
Emily M. Godfrey, MD
Clinical Instructor
Reproductive Health Program
Tel: 585-341-6290
Fax: 585-341-6293
HRP has collaborated with Chinese investigators in testing further the
efficacy of the 10 mg dose of mifepristone. During a
three-year collaborative initiative, funded by The Rockefeller Foundation, a
randomized, double-blind study was carried out including 3052 women in 10 centres around
Contact:
Helena von Hertzen
World Health Organization
1211
Email: vonhertzenh@who.ch
Gestrinone is a registered product and is used in
more than 40 countries for the treatment of endometriosis. In addition to its antigonadotrophic activity, the compound also has some antiprogestogenic activity. It is anticipated that due to
its fairly long duration of action - gestrinone is
administered twice weekly in the management of endometriosis - one dose of the
drug might be sufficient for effective emergency contraception. A randomized,
double-blind study was, therefore, launched in
Contact:
Helena von Hertzen
World Health Organization
1211
Email: vonhertzenh@who.ch
Several reports on the use of an IUD for emergency contraception suggested
that it could be highly effective for this indication. However, due to lack of
prospective, well-conducted studies on the efficacy and side-effects of the IUD
in EC, it was not possible to give any recommendations regarding its use. To
this end, a large multicentre study of the efficacy,
side-effects and acceptability of the TCu380A for emergency contraception was
launched in
Contact:
Helena von Hertzen
World Health Organization
1211
Email: vonhertzenh@who.ch
Several research initiatives have been planned together with the Programme's collaborating centres
to investigate possible mechanisms of action of emergency contraceptives. As
fecund cycles cannot be investigated in the human, a study was launched in
Helena von Hertzen
World Health Organization
1211
Email: vonhertzenh@who.ch
The American Society for Emergency Contraception (ASEC) is a voluntary
collaboration of organizations that promote the availability of emergency
contraception for women. Founded in 1997, ASEC has four mandates: 1) to
serve as a source of information for the media and others who want information
on emergency contraception; 2) to serve as a watchdog for inaccurate or biased
articles in the press and respond with accurate letters to the editor, and to
watch for abuses of reproductive rights related to emergency contraception, and
draw attention to these problems; 3) to promulgate policies on emergency
contraception and to support and disseminate the statements and guidelines of other
organizations willing to endorse the method; and 4) to link the members
of the emergency contraception field, primarily by sending out (in
collaboration with the international Consortium on Emergency Contraception)
this semi-annual electronic newsletter on recent events in emergency
contraception and by organizing an annual meeting (held on the first Monday in
October in New York) to share information with researchers, policy makers and
the pharmaceutical industry.
ASEC is open to industry participation, although it will not endorse one
method or regimen over others that are also safe and effective. Membership is
free, and although the focus is primarily on the
Tara Shochet
Executive Director
Tel: 609-258-2661
Email: AmSocEC@aol.com
The mission of the International Consortium for Emergency Contraception is
to expand access to and ensure safe and locally appropriate use of emergency
contraception worldwide within the broader context of family planning and
reproductive health, with emphasis on developing countries. The Consortium now
has 29 member agencies worldwide.
Recently, the Consortium was awarded funding by the Wallace Global Fund to
continue its program in three key areas: 1) Key information gathering and
dissemination on emergency contraception (EC), including enhancements to the
Consortium's Web site; 2) facilitation of collaboration and networking among
member organizations, other regional Consortia, the commercial sector and donor
community; and 3) advocacy for the promotion of EC methods and their safe and
effective use.
Single copies of the following publication can be requested free of charge
from the International Consortium:
While contained in the above publication, the Consortium has also published:
Susan McIntyre
Consortium Coordinator
Email: cecinfo@fhi.org